Literature DB >> 7820054

The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes.

E Matutes1, R Morilla, K Owusu-Ankomah, A Houliham, P Meeus, D Catovsky.   

Abstract

We have analysed the immunological profile of cells from 194 patients with a B-cell disorder associated with circulating hairy or villous lymphocytes. These included: 69 typical HCL, 25 HCL-variant and 100 splenic lymphoma with villous lymphocytes (SLVL). All cases were HLA-DR+, CD19+, CD2- and most expressed Smlg with light chain restriction. The kappa/lambda ratios were: HCL, 1.2; SLVL, 1.5; and HCL-variant, 0.55. The majority were FMC7+ (89-96% of cases) and membrane CD22+ (73-98% of cases) and often negative with CD5 and CD23, markers characteristic of chronic lymphocytic leukemia. CD24 was variably expressed ranging from 21% of cases in HCL-variant to 60% in HCL and 89% in SLVL; CD10 and CD38 were positive in one third of SLVL but usually negative in HCL and HCL-variant. Of the four markers considered typical of HCL, CD11c, CD25, HC2 and B-ly-7, CD25 and HC2 were consistently negative in HCL-variant and a minority of SLVL cases expressed CD25 or HC2+ or B-ly-7+; CD11c was positive in all three disorders (47 to 97% of cases). Based on the most common phenotype of typical HCL: CD11c+, CD25+, HC2+ and B-ly-7+, we propose a scoring system which considers the reactivity with each of these four markers and gives 1 point if positive and 0 points if negative. Scores range from 4 (typical of HCL) to 0 (atypical of HCL). 98% of HCL had high scores (3 or 4) whereas 88% of HCL-variant and 77% of SLVL scored 1 or 2 and no single case scored 3 or 4.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7820054

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  21 in total

1.  Splenic marginal zone lymphomas appear to originate from different B cell types.

Authors:  David W Bahler; J Ander Pindzola; Steven H Swerdlow
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

Review 2.  Hairy cell leukemia: update and current therapeutic approach.

Authors:  Latif Salam; Omar Abdel-Wahab
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

3.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias.

Authors:  L Ginaldi; M De Martinis; E Matutes; N Farahat; R Morilla; D Catovsky
Journal:  J Clin Pathol       Date:  1998-05       Impact factor: 3.411

4.  A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation.

Authors:  Xiaofeng Shi; Rong Ba; Haiyan You; Qian Jiang; Jiansong Huang; Jianhua Mao; Lanxiu Han; Shuo Zhang; Qin Zhuang; Xianqiu Yu; Lixia Wang; Yun Wang; Dongya Li; Wei Zhu; Yong Zhang; Yan Zhu; Xiaodong Xi
Journal:  Front Med       Date:  2017-10-27       Impact factor: 4.592

5.  Hairy cell leukaemia variant with periarticular joint infiltration and excellent radiotherapy response.

Authors:  Michael J McKay; Kirsty L Rady; Thomas A McKay
Journal:  Ann Transl Med       Date:  2017-04

6.  Contribution of immunophenotype in the diagnosis and classification of haemopoietic malignancies.

Authors:  E Matutes
Journal:  J Clin Pathol       Date:  1995-03       Impact factor: 3.411

7.  Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders.

Authors:  Girish Venkataraman; Christine Aguhar; Robert J Kreitman; Constance M Yuan; Maryalice Stetler-Stevenson
Journal:  Am J Clin Pathol       Date:  2011-10       Impact factor: 2.493

8.  Monoclonal antibody HBME-1 reacts with a minor subset of B cells with villous surface and can be useful in the diagnosis of hairy cell leukemia and other indolent lymphoproliferations of villous B lymphocytes.

Authors:  László Krenács; Judit Tóth-Lipták; Judit Demeter; Klára Piukovics; Zita Borbényi; Péter Gogolák; Eszter Sári; Enikő Bagdi
Journal:  Virchows Arch       Date:  2013-10-05       Impact factor: 4.064

Review 9.  Update on the biology and treatment options for hairy cell leukemia.

Authors:  Preetesh Jain; Naveen Pemmaraju; Farhad Ravandi
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 10.  Hairy cell leukemia-new genes, new targets.

Authors:  Robert J Kreitman
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.